In 2019, a tech entrepreneur named Bryan Johnson sold his company Braintree to PayPal for $800 million and subsequently decided to spend a reported $2 million per year attempting to reverse his biological age. Project Blueprint, as he called it, involves a precise daily protocol of diet, exercise, sleep, and over 100 measured biomarkers, guided by a team of physicians. Johnson's stated goal is to have the organs of an 18-year-old. He publishes his data publicly. By several biological age metrics, his body has responded. His proponents call him a pioneer. His critics call him a cautionary tale about wealthy men and their peculiar anxieties. What neither camp fully engages with is the underlying scientific question: is biological aging actually malleable, and if so, by how much?
That question has moved from the philosophical fringe to the center of mainstream biology over the past two decades. The field now called geroscience, the study of the relationship between aging and age-related disease, has generated a detailed mechanistic understanding of why cells and organisms age. In 2013, a landmark paper by Carlos Lopez-Otin and colleagues in the journal Cell systematically catalogued nine cellular hallmarks that drive aging, expanded to twelve in a 2023 update. Interventions targeting these hallmarks have extended lifespan in animals ranging from yeast to mice by 30 to 100 percent. The NIA's Interventions Testing Program has identified compounds that significantly extend mouse lifespan in rigorous multi-site trials. The question is no longer whether aging is biological and therefore potentially modifiable. It clearly is. The question is how much of the human aging process is amenable to intervention, and on what timeline.
This article traces the biology of aging from its cellular foundations through the most credible current interventions, distinguishing between what has been demonstrated in organisms other than humans, what has preliminary human evidence, and what remains speculation dressed in scientific vocabulary.
"Aging is not a mystery. It is a defined set of molecular and cellular processes that we are beginning to understand and, in some cases, to manipulate." -- Carlos Lopez-Otin, Biochemist, University of Oviedo, lead author of the Hallmarks of Aging framework
Key Definitions
Hallmarks of aging: Cellular and molecular processes that drive organismal aging, as defined by Lopez-Otin et al. (2013, 2023). The framework provides a classification system for understanding and targeting aging mechanisms.
Senescent cells: Cells that have permanently exited the cell cycle in response to damage but remain metabolically active, secreting a pro-inflammatory mixture of cytokines and proteases known as the senescence-associated secretory phenotype (SASP). Accumulation of senescent cells is a major driver of tissue dysfunction with aging.
Epigenetic clock: A biological age estimation tool developed by Steve Horvath at UCLA, based on DNA methylation patterns at specific sites in the genome. The Horvath clock correlates strongly with chronological age and with disease risk, and can be modified by lifestyle factors and interventions.
mTOR (mechanistic target of rapamycin): A central cellular nutrient-sensing kinase that promotes cell growth when nutrients are abundant. Chronically elevated mTOR activity with aging is associated with reduced autophagy, accelerated senescence, and shortened lifespan. Rapamycin inhibits mTOR and extends lifespan in multiple organisms.
Autophagy: The cellular process of degrading and recycling damaged proteins and organelles. Declines with age and is a key mechanism through which caloric restriction and fasting may promote longevity.
The Hallmarks of Aging: A Mechanistic Framework
When Lopez-Otin, Manuel Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer published "The Hallmarks of Aging" in Cell in June 2013, they provided the field with something it had lacked: a coherent, evidence-based classification system for the cellular and molecular processes driving biological aging. Their framework, modeled on Hanahan and Weinberg's influential "Hallmarks of Cancer" paper, identified nine characteristics that collectively represent the causes and consequences of biological aging. A 2023 update expanded the list to twelve.
The original nine hallmarks are: genomic instability (accumulation of DNA damage over time), telomere attrition (shortening of protective chromosome caps with each cell division), epigenetic alterations (changes in gene expression patterns independent of DNA sequence), loss of proteostasis (failure of protein quality control systems), deregulated nutrient sensing (changes in IGF-1, mTOR, AMPK, and sirtuin signaling), mitochondrial dysfunction (declining efficiency and increased reactive oxygen species production), cellular senescence (accumulation of dysfunctional cells that resist death), stem cell exhaustion (decline in tissue renewal capacity), and altered intercellular communication (changes in hormones, growth factors, and inflammatory signals).
The 2023 update added disabled macroautophagy (failure of cellular self-cleaning), chronic inflammation ("inflammaging" as a driving rather than merely consequential process), and dysbiosis (age-related changes in the gut microbiome affecting systemic health).
What makes this framework powerful is its actionability. Each hallmark is, in principle, a therapeutic target. Senolytics clear senescent cells. NAD precursors attempt to restore NAD-dependent signaling through sirtuins. Rapamycin inhibits mTOR to mimick caloric restriction effects. Autophagy-enhancing interventions including fasting attempt to restore cellular cleaning. The framework has organized a generation of research around specific mechanistic targets rather than vague notions of slowing aging.
Telomeres and the Hayflick Limit
In 1961, Leonard Hayflick discovered that human diploid cells in culture would divide approximately 50 times and then stop, entering a permanent non-dividing state. He proposed that cells have an intrinsic limit to their replicative capacity. This became known as the Hayflick limit. The molecular explanation was not found until decades later: with each cell division, the DNA sequences at the ends of chromosomes, called telomeres, shortened slightly because the DNA replication machinery cannot copy the very end of a linear chromosome.
The enzyme responsible for maintaining telomere length, telomerase, was discovered by Elizabeth Blackburn, Carol Greider, and Jack Szostak, who shared the 2009 Nobel Prize in Physiology or Medicine for this work. Blackburn's research at UCSF has documented associations between telomere length and various health outcomes, including cardiovascular disease, diabetes, and psychological stress. Her 2017 book with Elissa Epel, "The Telomere Effect," popularized the concept that lifestyle choices influence telomere length.
The relationship between telomeres and aging is real but complicated. Short telomeres are a reliable marker of biological aging. Telomerase activation in mice extends their lifespan substantially. But in humans, the evidence for telomere length as a causal driver of aging (rather than a marker) is less clear. Very long telomeres are associated with certain cancers, as telomerase activity is also a characteristic of cancer cells that must divide indefinitely. Clinical attempts to lengthen telomeres in humans are largely in early-stage research and raise safety concerns.
The more significant implication of Blackburn's work is that lifestyle factors that increase oxidative stress and chronic inflammation (psychological stress, poor sleep, sedentary behavior, smoking) accelerate telomere shortening. Conversely, regular exercise, mindfulness practice, and strong social connections are associated with longer telomeres, though causality is difficult to establish in observational data.
David Sinclair, NAD, and the Information Theory of Aging
David Sinclair, a professor of genetics at Harvard Medical School, has become the most prominent popularizer of longevity science for a general audience through his 2019 book "Lifespan: Why We Age, and Why We Don't Have To." Sinclair's central thesis is what he calls the information theory of aging: aging results not from the accumulation of mutations in DNA (which is rarer than commonly believed) but from the loss of the epigenetic information that specifies which genes are expressed in which cells.
His framework centers on sirtuins, a family of proteins that regulate gene expression in response to cellular stress. Sirtuins require NAD (nicotinamide adenine dinucleotide) as a co-factor, and NAD levels decline substantially with age. Sinclair argues that declining NAD reduces sirtuin activity, impairing the epigenetic maintenance that keeps gene expression patterns stable and appropriate.
The evidence for this framework is interesting but contested among longevity researchers. The sirtuin-longevity connection was initially reported in yeast and generated enormous excitement in the early 2000s. Resveratrol, a compound in red wine that activates sirtuins, became a major commercial phenomenon. Subsequent research found that many of the early resveratrol-sirtuin findings were artifacts of assay fluorescence interference. The direct evidence that boosting NAD through supplements (NMN or NR) extends human lifespan remains limited to preclinical animal studies, while human trials have shown metabolic effects without clear longevity endpoints.
Sinclair practices what he preaches: he takes NMN, metformin, resveratrol, and other compounds, tracks his biological age using epigenetic clocks, and claims to have meaningfully reduced his measured biological age. This self-experimentation generates interesting data but should not be confused with controlled trial evidence.
The most compelling part of Sinclair's framework is his discussion of epigenetic reprogramming. In 2006, Shinya Yamanaka (Nobel Prize 2012) demonstrated that mature adult cells could be reprogrammed into pluripotent stem cells using four transcription factors now called Yamanaka factors. In 2020, David Sinclair's lab published a paper in Nature demonstrating that partial expression of three of the four Yamanaka factors could restore vision in aged mice by epigenetically reprogramming retinal cells to a younger state. This finding, replicated in subsequent work, represents a genuine breakthrough: the demonstration that epigenetic aging is reversible in specific tissues. Whether it can be safely applied broadly to humans remains a major unsolved challenge.
Rapamycin and the mTOR Pathway
The most robust pharmacological evidence for lifespan extension in mammals involves rapamycin, an FDA-approved immunosuppressant drug that inhibits mTOR. In 2009, the National Institute on Aging's Interventions Testing Program reported that rapamycin extended median lifespan in genetically heterogeneous mice by 9 percent in males and 14 percent in females, even when treatment began at an age equivalent to approximately 60 years in humans. This was the first demonstration of lifespan extension by a pharmacological intervention begun in middle-aged mammals.
Subsequent ITP studies found that rapamycin extended maximum lifespan (the age at which the longest-lived individuals died) by 23 percent in males and 26 percent in females. The drug works through mTOR inhibition, which reduces protein synthesis, increases autophagy, and mimics several of the cellular effects of caloric restriction.
Mikhail Blagosklonny, a cancer biologist at Roswell Park Cancer Institute, has argued most forcefully that rapamycin is likely already the most effective anti-aging drug available to humans. He points to the drug's known safety profile from its use in organ transplant patients, and the extraordinary consistency of its longevity effects across diverse organisms including yeast, worms, flies, and mice. He has taken rapamycin himself for years and documents his reasoning publicly.
The caveats are significant. mTOR is involved in immune function, and rapamycin is an immunosuppressant; its chronic use in healthy people raises infection risk concerns. It impairs muscle protein synthesis, potentially exacerbating sarcopenia. And the extrapolation from mouse lifespan studies to humans is uncertain, as mice age quite differently from humans and interventions that work in mice have repeatedly failed to translate. Human clinical trials of rapamycin for aging prevention are underway but have not reported longevity endpoints.
Caloric Restriction: The Most Replicated Longevity Intervention
Caloric restriction (CR), reducing caloric intake by 20 to 40 percent without malnutrition, is the most consistently replicated lifespan-extending intervention in animal models. It extends lifespan in organisms ranging from yeast and Caenorhabditis elegans to mice, rats, and in studies of rhesus monkeys (though the monkey data is contested between two major research groups who obtained different results).
The mechanisms of CR are multiple: reduced IGF-1 signaling, mTOR inhibition (mimicking rapamycin), increased autophagy, reduced oxidative damage from lower metabolic rate, improved insulin sensitivity, and changes in gut microbiome composition. CR activates AMPK, a cellular energy sensor that promotes mitochondrial biogenesis and energy-efficient metabolism, while suppressing mTOR.
The CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial, the most rigorous human study of caloric restriction conducted under the NIH, randomized 218 non-obese adults to 25 percent caloric restriction or ad libitum eating for two years. The CR group achieved approximately 12 percent caloric reduction in practice. Results published in 2015 showed significant improvements in cardiometabolic risk factors, including reduced blood pressure, cholesterol, and inflammatory markers. A 2023 CALERIE paper in Nature Aging reported that CR slowed multiple biological measures of aging including an epigenetic pace-of-aging marker.
Whether CR extends human lifespan is unknown and may never be definitively tested in controlled trials. The Calorie Restriction Society, founded in 1994, includes long-term practitioners who voluntarily restrict calories by 10 to 30 percent. These individuals consistently show remarkable cardiometabolic health profiles, but whether they live longer than age-matched controls has not been established.
The Epigenetic Clock: Measuring Biological Age
Steve Horvath, a biostatistician at UCLA, published a landmark 2013 paper in Genome Biology introducing the first highly accurate epigenetic clock, a mathematical model that uses DNA methylation patterns at 353 specific genomic sites to estimate biological age with a median error of approximately 3.6 years. The Horvath clock is strikingly consistent across tissues: it predicts the same biological age from blood, brain, heart, liver, and other tissues, suggesting it captures a systemic aging process rather than tissue-specific changes.
Subsequent epigenetic clocks developed by Horvath and others (including the GrimAge and DunedinPACE clocks) have proven to be superior predictors of health span and lifespan than chronological age alone. GrimAge, which was trained on mortality outcomes rather than chronological age, is particularly powerful at predicting disease risk and time to death.
Importantly, epigenetic biological age is modifiable. A 2021 randomized controlled trial by Fitzgerald and colleagues found that an 8-week diet, sleep, exercise, and relaxation program reduced Horvath clock biological age by an average of 3.23 years compared to the control group. This is preliminary evidence from a small trial, but it represents a proof of concept that lifestyle intervention can shift measured biological age.
Blue Zones: What Longevity Populations Actually Do
Dan Buettner, working with National Geographic and demographers from Gianluca Pes and Michel Poulain, identified five populations with unusually high concentrations of people who reach age 100 while remaining healthy and functional: Sardinia, Italy (especially the Barbagia region); Okinawa, Japan; Loma Linda, California (Seventh-day Adventist community); the Nicoya Peninsula in Costa Rica; and Ikaria, Greece.
Buettner's 2008 book "The Blue Zones" and subsequent publications documented common lifestyle factors shared across these diverse populations. They eat predominantly plant-based diets (meat is consumed rarely in most Blue Zones, as a celebration food rather than a daily staple). They engage in regular moderate physical activity embedded in daily life, not structured gym workouts, but walking, gardening, and manual labor. They have strong social connections and community ties. They have a sense of purpose, what Okinawans call ikigai and Nicoyans call plan de vida. They experience moderate caloric intake, often through cultural practices like Okinawa's hara hachi bu, the practice of stopping eating at 80 percent fullness. And they have low rates of chronic stress.
What is striking about the Blue Zones is the absence of supplementation, biohacking, or pharmaceutical intervention. These populations achieve extraordinary longevity through the interaction of diet, movement, social connection, purpose, and stress management, all embedded in cultural practices that make healthy choices the default rather than a deliberate effort. Critics have noted some data quality issues in longevity records from some regions, particularly Sardinia and Ikaria, and have suggested that some of the longevity advantage may reflect pension fraud or poor birth record keeping. This is a legitimate methodological concern but does not negate the consistently favorable health profiles observed in these populations.
What Has Evidence vs. What Is Hype
The longevity landscape contains a great deal of enthusiastic speculation. Here is an honest assessment:
Strong evidence in humans: Not smoking; maintaining high cardiorespiratory fitness; maintaining healthy body weight; moderate alcohol consumption (or abstinence); quality sleep (7 to 9 hours); strong social connections; not being lonely. These factors are associated with 10 to 15 additional years of life in large prospective studies.
Moderate evidence in humans: Caloric restriction and its surrogates (time-restricted eating, plant-rich diets); Mediterranean-style dietary patterns; stress reduction through meditation and social support; preventing and treating metabolic syndrome.
Promising preclinical evidence, limited human evidence: Rapamycin for longevity; NAD precursors (NMN, NR); senolytics (dasatinib + quercetin); metformin in non-diabetic populations (TAME trial ongoing); epigenetic reprogramming.
Limited or no current evidence: Most commercially sold anti-aging supplements; most anti-aging skin treatments claiming systemic effects; cryonics; most longevity "stacks" promoted by biohackers.
The most honest statement about the current state of longevity science is that we understand aging mechanisms well enough to make specific interventions, but we have not yet demonstrated in controlled human trials that any pharmacological intervention meaningfully extends lifespan in healthy people. The lifestyle interventions with the strongest human evidence are almost boringly conventional: don't smoke, exercise, maintain healthy weight, sleep well, maintain social connections. That these recommendations require no subscription or expensive protocol is not evidence that they are wrong.
Practical Takeaways
Aging is biological and therefore subject to biological intervention. The research since 2000 has established this beyond reasonable doubt. Several mechanisms are now well enough understood to target.
The interventions with the best current evidence for extending healthy human life are lifestyle-based: cardiorespiratory fitness, strength training, not smoking, sleep, nutrition, and social connection. These can move epigenetic aging clocks by multiple years in clinical trials.
Rapamycin is the pharmacological intervention with the strongest animal longevity evidence. Human clinical testing is underway. People taking it off-label for longevity are running ahead of the evidence, which may be reasonable given its known safety profile, or may not be, given impaired muscle protein synthesis and immune effects.
Epigenetic reprogramming is the most scientifically exciting frontier. Sinclair's lab and several biotech companies are pursuing partial Yamanaka factor approaches. This technology is 5 to 15 years from clinical application at best.
For most people, the evidence-based priorities are: exercise consistently and ambitiously, don't be sedentary, maintain healthy body weight, sleep 7 to 9 hours, eat predominantly whole foods with substantial plants, don't smoke, limit alcohol, maintain meaningful social connections, and cultivate purpose.
See also What Exercise Actually Does to Your Body and Brain and How Epigenetics Works for deeper coverage of related mechanisms.
References
Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278.
Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
Sinclair DA, LaPlante MD. Lifespan: Why We Age, and Why We Don't Have To. Atria Books; 2019.
Horvath S. DNA methylation age of human tissues and cell types. Genome Biology. 2013;14(10):R115.
Ravussin E, Redman LM, Rochon J, et al. A 2-year randomized controlled trial of human caloric restriction: feasibility and effects on predictors of health span and longevity. Journals of Gerontology. 2015;70(9):1097-1104.
Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129.
Blackburn EH, Epel ES. The Telomere Effect: A Revolutionary Approach to Living Younger, Healthier, Longer. Grand Central Publishing; 2017.
Buettner D. The Blue Zones: Lessons for Living Longer from the People Who've Lived the Longest. National Geographic; 2008.
Fitzgerald KN, Hodges R, Hanes D, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging (Albany NY). 2021;13(7):9419-9432.
Das A, Huang GX, Bonkowski MS, et al. Impairment of an endothelial NAD-H2S signaling network is a reversible cause of vascular aging. Cell. 2018;173(1):74-89.
Calerie Phase 2 Study Group. Effect of 2-year caloric restriction on circulating levels of IGF-1, insulin, and insulin-like growth factor-binding proteins in nonobese men and women: a randomized clinical trial. Aging Cell. 2023 (updated analyses).
Frequently Asked Questions
What causes aging at the cellular level?
The 2013 Cell paper by Lopez-Otin and colleagues identified nine hallmarks of aging, expanded to twelve in 2023: genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication, plus disabled macroautophagy, chronic inflammation, and dysbiosis.
Can telomere lengthening reverse aging?
The evidence is mixed and largely preclinical. While short telomeres are associated with aging and disease, and telomerase activation can extend lifespan in mice, the relationship is not simple. Elizabeth Blackburn's Nobel Prize-winning research established telomeres as important aging markers, but interventions to lengthen telomeres in humans remain unproven for life extension and carry potential cancer risk.
What lifestyle factors have the most evidence for extending lifespan?
The strongest evidence supports: not smoking, maintaining high cardiorespiratory fitness, maintaining healthy body weight, not drinking excessively, good sleep, and strong social connections. Caloric restriction has robust evidence in animal models and some human data from CALERIE trial. The Blue Zone populations combine multiple protective factors simultaneously.
What anti-aging drugs are being studied?
Rapamycin (mTOR inhibitor) has the most robust longevity evidence in animal models, extending lifespan in multiple species including mice in the NIA Interventions Testing Program. Metformin is being studied in the TAME trial. NAD precursors (NMN, NR) are in early human trials. Senolytics to clear senescent cells are in early-phase clinical testing. None have proven longevity effects in healthy humans.
What are the longevity blue zones and what do they have in common?
Dan Buettner identified five Blue Zones with unusual concentrations of centenarians: Sardinia (Italy), Okinawa (Japan), Loma Linda (California), Nicoya Peninsula (Costa Rica), and Ikaria (Greece). Common features include plant-rich diets, regular moderate physical activity, strong social and community bonds, sense of purpose, moderate caloric intake, and low chronic stress. Importantly, no single Blue Zone uses supplements or biohacking.
Is calorie restriction the key to longevity?
Caloric restriction robustly extends lifespan in diverse animal models. The CALERIE trial in humans showed that 25 percent caloric restriction over two years improved multiple biomarkers of metabolic health and aging. However, whether it extends human lifespan is unknown, and implementation is difficult. It likely works through overlapping mechanisms including reduced IGF-1 signaling, mTOR inhibition, improved autophagy, and reduced oxidative stress.
How close are we to significantly extending human lifespan?
Most geroscientists consider a meaningful extension of healthy human lifespan within the next few decades plausible but uncertain. Aubrey de Grey's SENS framework identifies specific categories of cellular damage to repair. David Sinclair's information theory of aging proposes epigenetic reprogramming could reset biological age. Bryan Johnson's Project Blueprint documents aggressive multi-intervention tracking. The honest assessment is that current interventions extend healthspan (quality of life in older years) more clearly than they extend maximum lifespan.